TrialBritish journal of cancer2022

Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer.

Mark K Doherty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.